Antioxidant agents in neuroprotection treatment of glaucoma
Author:
E.A. EGOROV1, A.A. GVETADZE1, N.G. DAVYDOVA2
1The Russian National Research Medical N.I. Pirogov University; 2Helmholtz Moscow Research Institute of Eye Diseases
Summary:
Purpose was to study efficiency and safety of mexidol in combined therapy in patients with primary open-angle glaucoma (POAG). 94 patients (185 eyes) at the age of 18—75 years old with POAG I—III stages were divided into 3 groups: 50 patients received combined therapy of mexidol 100 mg and picamilon 150 mg, 22 patients received combined therapy of mexidol 300 mg and picamilon 150 mg, 22 patients received only picamilon 150 mg. All medicine was administered qd during 14 or 21 days. Examination included standard ophthalmologic methоds, perimetry, electroretinography, retinal and optic nerve heard arterial blood flow. Improvement of visual acuity, perimetric, electrofisiological indicies and increased blood flow velocity of central retinal artery were registrated. Combined mexidol therapy allows improving results in treatment of patients with POAG.
Keywords: Mexidol, picamilon, primary open-angle glaucoma, glaucomatous optic neuropathy, optic nerve heard.